Depression screening tools in persons with epilepsy: A systematic review of validated tools

Summary

Objective

Depression affects approximately 25% of epilepsy patients. However, the optimal tool to screen for depression in epilepsy has not been definitively established. The purpose of this study was to systematically review the literature on the validity of depression-screening tools in epilepsy.

Methods

MEDLINE, EMBASE, and PsycINFO were searched until April 4, 2016 with no restriction on dates. Abstract, full-text review and data abstraction were conducted in duplicate. We included studies that evaluated the validity of depression-screening tools and ...

Seguir leyendo →
0

WONOEP appraisal: Biomarkers of epilepsy-associated comorbidities

Summary

Neurologic and psychiatric comorbidities are common in patients with epilepsy. Diagnostic, predictive, and pharmacodynamic biomarkers of such comorbidities do not exist. They may share pathogenetic mechanisms with epileptogenesis/ictogenesis, and as such are an unmet clinical need. The objectives of the subgroup on biomarkers of comorbidities at the XIII Workshop on the Neurobiology of Epilepsy (WONOEP) were to present the state-of-the-art recent research findings in the field that highlighting potential biomarkers for comorbidities in epilepsy. We review recent ...

Seguir leyendo →
0

Clinical implications of SCN1A missense and truncation variants in a large Japanese cohort with Dravet syndrome

Summary

Objective

Two major classes of SCN1A variants are associated with Dravet syndrome (DS): those that result in haploinsufficiency (truncating) and those that result in an amino acid substitution (missense). The aim of this retrospective study was to describe the first large cohort of Japanese patients with SCN1A mutation–positive DS (n = 285), and investigate the relationship between variant (type and position) and clinical expression and response to treatment.

Methods

We sequenced all exons and intron–exon boundaries of SCN1A in ...

Seguir leyendo →
0

Clinical implications of SCN1A missense and truncation variants in a large Japanese cohort with Dravet syndrome

Summary

Objective

Two major classes of SCN1A variants are associated with Dravet syndrome (DS): those that result in haploinsufficiency (truncating) and those that result in an amino acid substitution (missense). The aim of this retrospective study was to describe the first large cohort of Japanese patients with SCN1A mutation–positive DS (n = 285), and investigate the relationship between variant (type and position) and clinical expression and response to treatment.

Methods

We sequenced all exons and intron–exon boundaries of SCN1A in ...

Seguir leyendo →
0

Verbal memory after temporal lobe epilepsy surgery in children: Do only mesial structures matter?

Summary

Objective

Previous findings have been mixed regarding verbal memory outcome after left temporal lobectomy in children, and there are few studies comparing verbal memory change after lateral versus mesial temporal lobe resections. We compared verbal memory outcome associated with sparing or including the mesial structures in children who underwent left or right temporal lobe resection. We also investigated predictors of postsurgical verbal memory change.

Methods

We retrospectively assessed verbal memory change approximately 1 year after unilateral temporal lobe epilepsy ...

Seguir leyendo →
0

Verbal memory after temporal lobe epilepsy surgery in children: Do only mesial structures matter?

Summary

Objective

Previous findings have been mixed regarding verbal memory outcome after left temporal lobectomy in children, and there are few studies comparing verbal memory change after lateral versus mesial temporal lobe resections. We compared verbal memory outcome associated with sparing or including the mesial structures in children who underwent left or right temporal lobe resection. We also investigated predictors of postsurgical verbal memory change.

Methods

We retrospectively assessed verbal memory change approximately 1 year after unilateral temporal lobe epilepsy ...

Seguir leyendo →
0

TRPC3 channels play a critical role in the theta component of pilocarpine-induced status epilepticus in mice

Summary

Objective

Canonical transient receptor potential (TRPC) channels constitute a family of cation channels that exhibit a regional and cell-specific expression pattern throughout the brain. It has been reported previously that TRPC3 channels are effectors of the brain-derived neurotrophic factor (BDNF)/trkB signaling pathway. Given the long postulated role of BDNF in epileptogenesis, TRPC3 channels may be a critical component in the underlying pathophysiology of seizure and epilepsy. In this study, we investigated the precise role of TRPC3 channels in ...

Seguir leyendo →
0

Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein

Summary

Objective

Brivaracetam (BRV) and levetiracetam (LEV) are effective antiepileptic drugs that bind selectively to the synaptic vesicle 2A (SV2A) protein. However, BRV differs from LEV in that it exhibits more potent and complete seizure suppression in animal models including in amygdala-kindled mice, where BRV afforded nearly complete seizure suppression. This raises the possibility that aside from potency differences, BRV and LEV may interact differently with the SV2A protein, which is not apparent in radioligand-binding competition studies. In this ...

Seguir leyendo →
0

Time to onset of sustained ≥50% responder status in patients with focal (partial-onset) seizures in three phase III studies of adjunctive brivaracetam treatment

Summary

Time to onset of sustained ≥50% responder status (SRS) was assessed for the pooled patient population receiving brivaracetam (BRV) 50, 100, or 200 mg/day or placebo in three randomized phase III studies (NCT00464269, NCT00490035, and NCT01261325). Patients were aged ≥16 years with well-characterized focal (partial-onset) seizures (FS) uncontrolled by 1–2 concomitant antiepileptic drugs. After an 8-week baseline period, patients received study drug without up-titration for a 12-week (84-day) treatment period. A patient was a sustained ≥50% responder ...

Seguir leyendo →
0

Time to onset of sustained ≥50% responder status in patients with focal (partial-onset) seizures in three phase III studies of adjunctive brivaracetam treatment

Summary

Time to onset of sustained ≥50% responder status (SRS) was assessed for the pooled patient population receiving brivaracetam (BRV) 50, 100, or 200 mg/day or placebo in three randomized phase III studies (NCT00464269, NCT00490035, and NCT01261325). Patients were aged ≥16 years with well-characterized focal (partial-onset) seizures (FS) uncontrolled by 1–2 concomitant antiepileptic drugs. After an 8-week baseline period, patients received study drug without up-titration for a 12-week (84-day) treatment period. A patient was a sustained ≥50% responder ...

Seguir leyendo →
0
Página 168 de 190 «...140150160166167168169170...»